MiSaver® Stem Cell Treatment for Acute Myocardial Infarction

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Acute Myocardial Infarction
Interventions
DRUG

MiSaver

"MiSaver vials was thawed using a thermostat-controlled mini bath, drawn into a 20ml syringe, and diluted with normal saline and intravenous infused following standard operating procedures, consecutively, until reasching the dosage.~Patients were premedicated with intravenous antihistamines (such as diphenhydramine) and corticosteroids (such as hydrocortisone) 30-60 minutes before the stem cell infusion. Any unused solution was discarded, and the total volume of injected solution was adjusted to accommodate the total daily fluid volume administered."

Trial Locations (1)

Unknown

Chung Shan Medical University Hospital, Taichung

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Chung Shan Medical University

OTHER

lead

Honya Medical Inc

INDUSTRY

NCT06353958 - MiSaver® Stem Cell Treatment for Acute Myocardial Infarction | Biotech Hunter | Biotech Hunter